In recent years, interest has grown in using injectable medications to treat type 2 diabetes and obesity.  Among these options, Mounjaro and Ozempic are developed to tackle the combined challenges of diabetes and weight management.

Both medications are GLP-1 receptor agonists but differ in their formulations, intended uses, effectiveness, and side effect profiles.

Continue reading to discover how these medications work, along with their key similarities and differences.

Mounjaro (Tirzepatide): Understanding the Alternative

Mounjaro represents a breakthrough in diabetes and weight management treatment. As a dual GIP and GLP-1 receptor agonist, it offers a novel approach to blood sugar control and weight loss.

Key Features:

• First-in-class dual-action medication

• Once-weekly injectable medication

• FDA-approved for type 2 diabetes

• Significant weight loss potential

• Available in multiple dose strengths

Research has shown that Mounjaro users experienced an average 22% reduction in body weight, making it one of the most effective weight loss medications currently available.

Ozempic (Semaglutide): A Closer Look

Ozempic has established itself as a reliable option for diabetes management and weight loss. As a GLP-1 receptor agonist, it helps regulate blood sugar and reduce appetite.

Key Features:

• Proven GLP-1 receptor agonist

• Once-weekly injection

• FDA-approved for type 2 diabetes

• Demonstrated weight loss benefits

• Well-studied safety profile

Similarities between Mounjaro and Ozempic

Both medications are once weekly subcutaneous (under the skin injections), which start with a low dose and increase to a maintenance dose.

They also may cause similar side effects, including:

• Nausea

• Diarrhoea

• Vomiting

• Constipation

• Abdominal pain

These effects typically decrease over time as your body adjusts to the medication. However, it’s essential to consult with a pharmacist who can consider your complete medical history.

Which is better for weight loss- Mounjaro or Ozempic?

Mounjaro (Tirzepatide): The up to 22% body weight reduction statistic is based on findings from the SURMOUNT-1 clinical trial, which evaluated tirzepatide specifically for weight loss in individuals without diabetes. Participants who took the highest dose (15 mg) experienced an average weight loss of about 21-22.5% over a 72-week period. This trial was published in The New England Journal of Medicine and showed Mounjaro’s significant effectiveness in weight reduction when combined with lifestyle interventions.

Ozempic (Semaglutide): The 15-17% body weight reduction range is sourced from the STEP clinical trials, particularly STEP 1 and STEP 4. In these studies, participants taking the 2.4 mg dose of semaglutide (marketed as Wegovy for obesity and as Ozempic for type 2 diabetes) lost around 15-17% of their body weight on average over a 68-week period.

These findings were also published in The New England Journal of Medicine and are frequently cited in treatment guidelines for obesity and diabetes management.

Which Medication is Right for You?

Making an informed decision about weight loss medication requires professional guidance. Our pharmacists can help you determine which medication is best based on your:

• Medical history
• Weight loss goals
• Personalised treatment plan

Ready to explore your weight loss medication options?

Book your consultation today and connect with an expert pharmacist in your area – click here to get started.